Breaking News, Collaborations & Alliances

Lilly, Vir, GSK Partner to Evaluate COVID Combo Therapies

Lilly expands BLAZE-4 trial to evaluate bamlanivimab with VIR-7831, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly, Vir Biotechnology, and GlaxoSmithKline have entered a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein.   Bamlanivimab is a neutralizing antibody directed against the spik...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters